Premium
Pharmaceutical review
Author(s) -
O'Reilly P.
Publication year - 2003
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1046/j.1464-410x.2003.t01-4-04278.x-i1
Subject(s) - citation , library science , computer science
© 2 0 0 3 B J U I N T E R N A T I O N A L | 9 2 , 3 3 0 – 3 3 2 | doi:10.1046/j.1464-410X.2003.04336.x doxazosin alone was not significantly different from placebo. Similarly, only the combination and finasteride arms significantly reduced the incidence of invasive therapy for BPH (a risk reduction of 69% and 64% vs placebo, respectively). Again, the difference in risk reduction was not clinically significant between the finasteride and combination groups. As with the incidence of AUR, there was no significant benefit with doxazosin in the incidence of surgery over placebo after 5.5 years.